Wired News – OPKO Health Announced Enrollment of First Patient in Phase-2b Trial of OPK88003 to Treat Type-2 Diabetes

Stock Monitor: Capricor Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on OPKO Health, Inc. (NASDAQ: OPK). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPK as the Company’s latest news hit the wire. On March 23, 2018, the Company announced that it has enrolled the first patient in a Phase-2b dose escalation trial of OPK88003, a once-weekly oxyntomodulin therapy containing dual agonist activity towards GLP-1 and Glucagon receptors, to treat type-2 diabetes and obesity. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Capricor Therapeutics, Inc. (NASDAQ: CAPR), which also belongs to the Healthcare sector as the Company OPKO Health. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CAPR

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, OPKO Health most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=OPK

The Primary Endpoint of Phase-2b Trial is to Evaluate a Dose Escalation Regimen of OPK88003

The Phase-2b trial will enroll approximately 110 patients with type-2 diabetes at up to 35 clinical sites in the US. The primary endpoint of the study is to evaluate a dose escalation regimen of OPK88003 to reduce HbA1c levels over a 30-week treatment period. The study will also assess weight loss and lipid composition, the secondary endpoints.

Dual Agonist Activity of OPK88003 May Provide Improved Benefits in Treatment of Diabetes

Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO Health, stated that the Company’s confidence in this program is supported by the earlier Phase-2 data and it is enthusiastic to be initiating this study in type-2 diabetics to evaluate the effects of a refined dosing regimen of oxyntomodulin on glucose control and weight loss in preparation for a pivotal Phase-3 program.

Phillip added that the dual agonist activity of OPK88003 may provide improved benefits in the treatment of diabetes, resulting in better glucose control and improved long-term cardiovascular outcomes. OPKO Health believes OPK88003 has the potential to offer improved benefits compared to the current once-weekly GLP-1 therapies in a growing diabetes market.

OPKO Expects to Initiate Phase-2b Dose-Escalation Study with OPK88003 in Q2 2018

News report suggest that OPKO expects to initiate a Phase-2b dose-escalation study with OPK88003 in Q2 2018. OPK88003 was previously evaluated in a blinded Phase-2 clinical trial of 420 patients with type-2 diabetes for 12 weeks, followed by an open label extension for an additional 12 weeks. The study showed that OPK88003 reduced HbA1c levels by approximately 1.4% and resulted in statistically superior weight loss compared to the comparator, a weekly exenatide. Furthermore, OPK88003 treatment resulted in a favorable decrease in triglycerides and cholesterol in comparison to the weekly exenatide.

About Type-2 Diabetes

Diabetes is a problem with the body that causes blood glucose (sugar) levels to rise higher than normal. This is also called hyperglycemia. Type-2 diabetes is the most common form of diabetes. In type-2 diabetes, the pancreas still makes insulin, but the cells cannot use it very efficiently. Type-2 diabetes is associated with modifiable lifestyle risk factors. It also has strong genetic and family related risk factors.

About OPKO Health, Inc.

Founded in 2007 and headquartered in Miami, Florida, OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. The Company’s diagnostics business includes BioReference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team.

Stock Performance Snapshot

March 26, 2018 – At Monday’s closing bell, OPKO Health’s stock rose 1.53%, ending the trading session at $3.32.

Volume traded for the day: 4.99 million shares, which was above the 3-month average volume of 4.93 million shares.

After yesterday’s close, OPKO Health’s market cap was at $1.88 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.9% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 494342